In a phase I study of NKG2D CAR-T cells for patients with R/R AML and myelodysplastic syndromes (MDS) or MM, the best ORR of 12 evaluable patients with R/R AML or MDS was 25% at a median follow-up of 118 days, and no therapy-related deaths was observed (65). This evidence concerns the gene KLRK1 and myelodysplastic syndrome.